Ciltacabtagene autoleucel (Carvykti®). HTA ID: 24021

Assessment Status Rapid Review complete
HTA ID 24021
Drug Ciltacabtagene autoleucel
Brand Carvykti®
Indication For the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
Assessment Process
Rapid review commissioned 04/06/2024
Rapid review completed 08/07/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ciltacabtagene autoleucel for this indication compared with the current standard of care.